Cara Therapeutics, (NASDAQ:CARA) known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on Friday, March 11 from 1:00 to 2:00 p.m. ET. The presentation will focus on the initiation of oral difelikefalin Phase 3 programs for the treatment of pruritus in patients with atopic dermatitis and non-dialysis dependent chronic kidney disease.
An interactive Q&A session will follow the presentation.
Presenters will include:
Christopher Posner, president & CEO and director of Cara Therapeutics
- Joana Goncalves, MD, chief medical officer of Cara Therapeutics
- Brian Kim, MD, MTR,
- Jonathan Silverberg, MD, Ph.D., MPH
